Milford-based SeraCare Life Sciences has launched two new circulating tumor DNA (ctDNA) products that will allow researchers to better understand the effectiveness of their treatments.
The (ctDNA) products — Seraseq Circulating Tumor DNA-I Reference Material and Seraseq Circulating Tumor DNA-I Mutation Mix Kit — are used to research the effectiveness of cancer treatments on circulating tumor DNA that may only be present on the order of a few dozen copies in a nominal blood draw. These products from the in vitro diagnostics manufacturer will give researchers a known quantity of material.
“The Seraseq biosynthetic technology is very powerful and flexible, capable of accommodating any number of mutations and allelic frequencies, providing excellent, high-quality tools for anyone developing, analytically validating or tracking daily performance of a ctDNA assay,” said Dale Yuzuki, director of market development from SeraCare Life Sciences.
